COA's Nicolas Ferreyros on the Senate PBM Hearing and the FTC Investigation
Nicolas Ferreyros, managing director at Community Oncology Alliance (COA), discusses the recent Senate commerce hearing on pharmacy benefit managers (PBMs), which brought bipartisan attention and energy towards addressing the concerns related to PBMs in Washington.
Disparities Exist in Patient Selection for ECMO, Study Finds
A study including data from more than 2 million patients highlights gender, health insurance, and income disparities in patients receiving extracorporeal membrane oxygenation (ECMO) while hospitalized for severe respiratory illness.
Dr Davey Daniel on the Importance of Biomarker Tests for Patients With Lung Cancer
Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.
Dr Debra Patt: Consolidation and New Advanced Therapies in Oncology
Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses financial drivers affecting community oncology as well as new advances within cancer care that allow it to be treated as a chronic disease.
Nicolas Ferreyros: There Is Growing Recognition the 340B Program Is "Out of Control"
Growing bipartisan awareness of issues with the 340B drug pricing program will hopefully lead to reform, says Nicolas Ferreyros, BA, managing director of policy, advocacy, and communications at the Community Oncology Alliance.
Nicolas Ferreyros: COA's 2023 Community Oncology Conference Celebrating 2 Decades of Achievements
This year's Community Oncology Conference will celebrate 2 decades of achievements in community oncology and begin to chart a path forward for the future, said Nicolas Ferreyros, managing director of policy, advocacy, and communications at Community Oncology Alliance (COA).